8E8.F ELICERA THERAPEUTICS AB
- Market cap
- EUR 13.6M
- P/E
- -
- P/B
- 2.68x
- ROE
- -40.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8E8.F undervalued?
Graham numberThe Graham number of ELICERA THERAPEUTICS AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ELICERA THERAPEUTICS AB fundamental analysis
No fundamental analysis for ELICERA THERAPEUTICS AB yet.
ELICERA THERAPEUTICS AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ELICERA THERAPEUTICS AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatm…
Full company profileELICERA THERAPEUTICS AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ELICERA THERAPEUTICS AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -19.4M | -17.1M | -16.9M | -17.9M | -22.8M |
| EBITDA | -19.3M | -16.3M | -16.0M | -17.4M | -22.6M |
| Net Income | -19.4M | -16.4M | -16.1M | -17.4M | -22.6M |
| EPS | -0.96 | -0.81 | -0.45 | -0.35 | -0.34 |
| Balance Sheet | |||||
| Total Assets | 46.3M | 30.2M | 27.6M | 27.4M | 59.6M |
| Total Liabilities | 13.5M | 13.8M | 6.80M | 4.06M | 3.35M |
| Shareholders' Equity | 32.8M | 16.4M | 20.8M | 23.4M | 56.3M |
| Cash & Short-term Investments | 43.8M | 29.4M | 26.4M | 24.8M | 58.1M |
| Cash Flow | |||||
| Operating Cash Flow | -8.57M | -14.9M | -23.5M | -21.6M | -21.9M |
| Capital Expenditure | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -8.57M | -14.9M | -23.5M | -21.6M | -21.9M |
| Ratios | |||||
| ROE | -59.3% | -100.0% | -77.6% | -74.5% | -40.3% |
| ROA | -42.0% | -54.3% | -58.4% | -63.5% | -38.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ELICERA THERAPEUTICS AB dividends
ELICERA THERAPEUTICS AB has not paid dividends in the last 4 fiscal years.
Who owns ELICERA THERAPEUTICS AB
- Insiders 24.70%
- Institutions 16.47%
- Public & others 58.83%
- Shares outstanding 66.7M
- Free float 48.4M
ELICERA THERAPEUTICS AB company profile
- Company name
- ELICERA THERAPEUTICS AB
- Ticker
- 8E8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- World Trade Center Göteborg, Gothenburg, Sweden, 412 51
- Phone
- 46 7 03 31 90 51
- Website
- elicera.com
About ELICERA THERAPEUTICS AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in late preclinical evaluation stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
ELICERA THERAPEUTICS AB management
4- Mr. Di YuCo-Founder, Acting Chief Scientific Officer, Chief Development Officer & Director · born 1985
- Prof. Magnus EssandChief Science Officer, Co-Founder & Director (Leave of Absence) · born 1964
- Mr. Johan LiwingChief Executive Officer · born 1974
- Mr. Ingvar KarlssonChief Financial Officer · born 1956